Safety, pharmacokinetics, and pharmacodynamics of drotrecogin alfa (activated) in children with severe sepsis.
Weiss
Karen D
KD
Office of Drug Evaluation VI, Office of New Drugs, Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, MD 20852, USA. weissk@cber.fda.gov
D018806:APACHE; D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D011486:Protein C / Q000627:therapeutic use*; D011994:Recombinant Proteins / Q000627:therapeutic use*; D018805:Sepsis / Q000188:drug therapy* / Q000401:mortality
D005343:Fibrinolytic Agents; D011486:Protein C; D011994:Recombinant Proteins; C421124:drotrecogin alfa activated